Cutaneous tumors with melanocytic differentiation represent a broad group of neoplasms of both melanocytic and non-melanocytic origin. Besides traditional members such as clear-cell sarcoma (CCS) and PEComa, the latter group has recently expanded to also include MITF::CREM fusion-associated tumors, but the available data are limited. Herein, we present a third case of this rare neoplasm which occurred in the temporal region in a 1-year-old girl. It was an infiltratively growing polypoid dermal-based lesion lacking an intraepidermal component. It consisted of cellular solid sheets or small nests of epithelioid to spindled cells with a predominantly eosinophilic and much less commonly clear cytoplasm. The nuclei had round to ovoid shape and exhibited moderate to high-grade atypia and prominent nucleoli. The mitotic activity was 11 mitoses per 10 high-power fields, and atypical mitotic figures were present. Immunohistochemically, the tumor was strongly positive with S100 protein, SOX10, and MITF, while HMB45, tyrosinase, and Melan A were negative. Extensive molecular analysis revealed only MITF::CREM gene fusion. There had no evidence of disease 9 months after the diagnosis. These tumors need to be distinguished from malignant tumors with melanocytic differentiation, primarily from melanoma. However, additional cases still need to be studied to precisely define their biological potential and establish their nosologic status.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00428-023-03621-7 | DOI Listing |
Background And Aims: Spitz nevus is a rare benign tumor classified among unusual melanocytic nevi. This study aimed to identify the demographic, clinical, and histopathological characteristics of Spitz nevus among Iranian patients.
Methods: This descriptive, retrospective study involved reviewing the records of patients diagnosed with Spitz nevus at a referral and academic hospital in Iran between 2016 and 2021.
Front Immunol
December 2024
Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
Melanoma of the uveal tract or uveal melanoma (UM) originates from melanocytes of the eye and is the most common intraocular malignancy in adults. Despite considerable advances in diagnostic procedures and treatments, prognosis remains poor in those with advanced disease. Accordingly, although current treatments have an excellent local disease control rate, approximately 50% of patients develop metastatic relapse within 10 years.
View Article and Find Full Text PDFInt J Mol Sci
November 2024
Department of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagaki, Suzuka 513-8607, Japan.
Melanomas, which develop on malignant transformations of melanocytes, are highly malignant and prone to metastasis; therefore, effective drugs are required. The (MC) extract has been shown to suppress cancer cell proliferation and invasion; however, the effect of the MC extract on melanoma in living organisms remains unclear. In this study, we investigated the mechanism underlying the amelioration of melanoma cell extravasation into mouse lungs by the MC extract.
View Article and Find Full Text PDFCancers (Basel)
December 2024
Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig Maximilians University, 80336 Munich, Germany.
Two-pore channel 2 (TPC2) is expressed in endolysosomes throughout the human body, as well as in melanosomes of melanocytes. Melanocytes produce pigment, i.e.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
December 2024
Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: When monitoring melanocytic neoplasms, the pattern of change may distinguish nevi from melanoma. Anticipating the growth dynamics of nevi based on their dermoscopic pattern is important to make this distinction.
Objective: The primary aim was to examine the association between nevus dermoscopic pattern at baseline and diameter change during long-term monitoring.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!